Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
event icon
What Bioprocessing Professionals Think About the KrosFlo® KR2i Tangential Flow Filtration System
Supporting academics, start-ups, CDMOs, and large biotech companies alike, the KrosFlo® KR2i tangential flow filtration (TFF) system continues to be a staple in the industry after 10+ years of ongoing innovation. Have you ever wondered why it’s gained such a following and if it’s a fit for your unique process? What happens when you hand over the mic to people who use this tried-and-true system every single day? In this webinar, ReciBioPharm and KBI Biopharma will pull back the curtain on their real-world experiences with the KrosFlo KR2i TFF system. From accelerating development timelines to solving unexpected bottlenecks, they’ll share the wins, the surprises, and the lessons learned along the way. Whether you're evaluating new TFF systems, looking to switch platforms, or already using the KrosFlo KR2i system and wanting to optimize your process, this is your chance to hear directly from real-world users. Key Takeaways: Performance highlights and challenges from real-world applications. Best practices and lessons learned from experienced users. Tips for achieving consistent and scalable TFF results.
external link icon
Repligen Corporation to Present at Upcoming May Investor Conferences
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
RBC Capital Markets’ 2024 Global Healthcare Conference, being held in New York on May 14-15. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 14, 2024 at 10:30 a.m. ET, in addition to a series of one-on-one meetings with investors. Craig-Hallum’s 21 st Annual Institutional Investor Conference, being held in Minneapolis on May 29. Jason K. Garland, Chief Financial officer will participate in a series of one-on-one meetings with investors. Leerink Partners’ 2024 Healthcare Crossroads Conference, being held in Austin, Texas on May 28-29. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 30, 2024 at 8:40 a.m. CT, in addition to a
external link icon
Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (“Purolite”), for the development and manufacturing of affinity ligands focused on monoclonal antibodies (“mAb”) and antibody fragments. Repligen entered into an exclusive agreement with Purolite in 2018 for the development and supply of NGL-Impact ® Protein A ligands. This agreement extends our exclusive partnership to 2032 and broadens the scope of the partnership to now include ligands targeting mAb fragments. Tony J. Hunt, President and CEO of Repligen, said, “We are delighted with the progress we have made working with Purolite and now Ecolab to establish the NGL family of Protein A ligands in the marketplace. This extension and product line expansion is well aligned with our Proteins strategy and supports the acceleration in market adoption of the Praesto ® affinity resin portfolio. It provides
external link icon
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at three upcoming investor conferences.
Craig-Hallum’s 19 th Annual Institutional Investor conference being held June 1. Management will be hosting one-on-one meetings with investors who are registered to attend the conference. William Blair’s 42 nd Annual Growth Stock Conference being held in Chicago June 6-9. Tony J. Hunt, President and Chief Executive Officer, is scheduled to present a company overview on June 7, 2022 at 10:40 a.m. CDT. Jefferies’ Global Healthcare Conference being held in New York June 8-10. Jon K. Snodgres, Chief Financial Officer, is scheduled to present a company overview on June 9, 2022 at 9:30 a.m. EDT. A live webcast of the William Blair and Jefferies conference presentations will be accessible through Repligen’s  Investor Relations website at
external link icon
Repligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands
Waltham, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that is has extended a long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen’s facilities in Waltham, MA and Lund, Sweden. Repligen is the main strategic supplier of Protein A ligands to Purolite, an emerging player in the Protein A resin market with its Praesto® line of modern agarose-based, high-flow chromatography resins. Pursuant to the agreement, Repligen will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025. Protein A chromatography remains the gold standard for monoclonal antibody purification, consistently providing outstanding results.  Steve Tingley, VP of Sales for Repligen said, “We are delighted that Purolite has made the decision to extend our current supply agreement, which ensures the supply of high quality Protein A ligands to Purolite for the next five to eight
external link icon
Repligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021
WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) today announced the pricing of an underwritten public offering of $100 million aggregate principal amount of 2.125% Convertible Senior Notes due 2021 (the “Notes”). The Company has granted the underwriters a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes. The offering is expected to close on or about May 24, 2016, subject to customary closing conditions. Jefferies is acting as the sole book-running manager, and Janney Montgomery Scott and Craig-Hallum Capital Group are acting as co-managers in the offering.  Perella Weinberg Partners LP and J. Wood Capital Advisors LLC are serving as financial advisors to the Company in connection with the offering.
Interest on the Notes will be paid semiannually in arrears on June 1 and December 1 of each year at the rate of 2.125% per year, beginning on December 1, 2016. The Notes will
external link icon
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due 2021 (the “Notes”) in an underwritten offering which includes the grant to the underwriter of a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes.  Jefferies is the sole book-running manager for the offering. 
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  The Notes will be issued and sold pursuant to an automatically effective shelf registration statement (including a base prospectus) that was previously filed with the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to this offering will be filed with the SEC. When available, copies of the
external link icon
Repligen Reports First Quarter 2016 Financial Results
WALTHAM, Mass., May 05, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the first quarter ended March 31, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call.
Tony J. Hunt, President and Chief Executive Officer, said, “Our record revenue during the first quarter reflects overall growth of 21% year-over-year, driven by increased demand for our proprietary products, which we believe is a direct result of our commercial expansion in 2015. We continue to add best-in-class technologies to our portfolio, and we closed out the quarter by executing on our acquisition strategy with our April 1 st purchase of Atoll GmBH (“Atoll”). We are pleased with how the integration is progressing and look forward to
event icon
Four Common Pitfalls to Avoid in UF/DF Setup and Scale-Up
Ultrafiltration Diafiltration (UF/DF) processes that look robust at the development scale often expose critical weaknesses during scale-up or tech transfer—resulting in capacity constraints, excessive manual intervention, delayed timelines, or manufacturing risk. In many cases, these issues trace back to early UF/DF decisions that seemed reasonable at the time but didn’t fully account for scalability, system design, or cross-functional alignment. In this webinar, we’ll break down four of the most common—and costly—pitfalls in UF/DF setup and scale-up, including poor filter sizing and membrane selection, overreliance on manual operations, system design limitations, and breakdowns in communication between Process Development and MSAT teams. Through practical examples drawn from downstream workflows, we’ll show how these pitfalls emerge, why they persist, and how they impact process robustness and manufacturing success. Viewers will leave with practical strategies to design more scalable UF/DF processes, reduce manual burden, improve system selection, and strengthen PD–MSAT collaboration—helping teams avoid late-stage surprises and enabling smoother tech transfer to manufacturing. Avoid scale-up surprises with membrane selection strategies that are fit-for-purpose Reduce manual burden and operational risk by understanding when automation and system design choices matter most for robust, scalable UF/DF operations Enable smoother tech transfer by improving alignment and communication between Process Development and MSAT teams early in process design
video icon
Implementing PAT strategy using in-line concentration monitoring in batch/continuous chromatography (Seagen)
As Seagen steps into next-gen processing, continuous processing has been one of their major area of focus for 2022. With the increasing production demands, process intensification requirements are increasing as well. To meet this, in-line process analytical technology (PAT) can enable comfortable processing. A steppingstone to this was our evaluation of VPX for further concentrating harvests and improving the chromatography efficiencies. Speaker: Aishwarya Ramanan, Senior Research Associate – Seagen.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support